WuXi PharmaTech Reports $500 Million in 2012 Revenues
WuXi PharmaTech reported another year of steadily increasing growth for 2012, something it seems to do with metronomic regularity. In 2012, the company’s net revenues rose 23% to just under $500 million and earnings (GAAP) climbed 7% to $86.6 million. WuXi’s mainstay business, China-based laboratory services, led the charge, rising almost 27% to $293 million. Manufacturing revenues increased 22.5% to $117 million, and US laboratory services were up 12% to $90 million. More details.... Stock Symbol: (NYSE: WX) Share this with colleagues: // //  
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here